ResearcherHenry Ford Health + Michigan State University Health SciencesActive in the last 2 years

Shyam Nyati

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1435-303X; OpenAlex author ID A5065899903. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 2)
Trials: 0
Grants: 0
Labs led: 1
Collaborators: 4

Papers, trials and grants by year

2024: 2 papers

Papers 2

Long-Term Follow-Up of Phase I Trial of Oncolytic Adenovirus-Mediated Cytotoxic and Interleukin-12 Gene Therapy for Treatment of Metastatic Pancreatic Cancer. Last author DOI 10.3390/biomedicines12051065 ↗
Optimizing Pancreatic Cancer Therapy: The Promise of Immune Stimulatory Oncolytic Viruses. Last author DOI 10.3390/ijms25189912 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Aseem Rai Bhatnagar · 2 shared papers, 2024 · strength 0.54
- Paper Optimizing Pancreatic Cancer Therapy: The Promise of Immune Stimulatory Oncolytic Viruses. DOI 10.3390/ijms25189912 ↗
- Paper Long-Term Follow-Up of Phase I Trial of Oncolytic Adenovirus-Mediated Cytotoxic and Interleukin-12 Gene Therapy for Tre… DOI 10.3390/biomedicines12051065 ↗
Shivani Thoidingjam · 1 shared paper, 2024 · strength 0.28
- Paper Optimizing Pancreatic Cancer Therapy: The Promise of Immune Stimulatory Oncolytic Viruses. DOI 10.3390/ijms25189912 ↗
David Kwon · 1 shared paper, 2024 · strength 0.26
- Paper Long-Term Follow-Up of Phase I Trial of Oncolytic Adenovirus-Mediated Cytotoxic and Interleukin-12 Gene Therapy for Tre… DOI 10.3390/biomedicines12051065 ↗
Gazala Naaz Khan · 1 shared paper, 2024 · strength 0.26
- Paper Long-Term Follow-Up of Phase I Trial of Oncolytic Adenovirus-Mediated Cytotoxic and Interleukin-12 Gene Therapy for Tre… DOI 10.3390/biomedicines12051065 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.